Post-earnings recap
Reported
Thu, Apr 25, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bristol-Myers Squibb reported a significant loss in EPS, which contributed to an 8.51% decline in stock price. The lack of revenue data and guidance leaves investors uncertain about the company's future performance. The large EPS miss suggests potential challenges that may need to be addressed in upcoming quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-4.40 | N/A | -387.21% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.